New drug combo aims to shrink Hard-to-Treat tumors
NCT ID NCT06462794
First seen Mar 24, 2026 · Last updated Apr 30, 2026 · Updated 4 times
Summary
This early study tests a new drug called CX-801, alone or with pembrolizumab, in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the best dose. About 121 people will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
University of Pittsburgh Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.